Resorufin: a lead for a new protein kinase CK2 inhibitor
- PMID: 19177021
- DOI: 10.1097/CAD.0b013e328326472e
Resorufin: a lead for a new protein kinase CK2 inhibitor
Abstract
Screening a natural compound library led to the identification of resorufin as a highly selective and potent inhibitor of protein kinase CK2. Out of 52 kinases tested, only CK2 was inhibited, in contrast to emodin, a structurally related, known CK2 inhibitor that, in addition to CK2, inhibited ten other kinases by 90%. The IC50 values determined for the CK2 holoenzymes were 1.5 mol/l and for the free catalytic subunits ca. 4 mol/l. Altogether four cell lines were subjected to resorufin and emodin treatment. In the case of the three prostate carcinoma cell lines (PC-3, DU-145, LNCaP), 24 h treatment with 40 mol/l resorufin led to 15-20% dead cells; however, no caspase-mediated apoptosis was observed. In the case of the colorectal carcinoma HCT116 cell line, a similar picture was obtained, yet, when resorufin was administered to cells treated with doxorubicin, apoptosis was strongly induced within 24 h. Endogenous protein kinase CK2 was inhibited by resorufin by ca. 80% in the three prostate cell lines. In the case of the HCT116 cells, the inhibition was only 40% supporting the notion of cell line-specific selectivity. Moreover, we analysed the effect of resorufin and emodin on selected signalling molecules in the cell lines under investigation.
Similar articles
-
p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.Prostate. 2010 Feb 1;70(2):126-34. doi: 10.1002/pros.21044. Prostate. 2010. PMID: 19760628
-
Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells.Prostate. 2007 Feb 1;67(2):125-34. doi: 10.1002/pros.20471. Prostate. 2007. PMID: 17044081
-
Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.Int J Biochem Cell Biol. 2007;39(1):227-37. doi: 10.1016/j.biocel.2006.08.006. Epub 2006 Aug 30. Int J Biochem Cell Biol. 2007. PMID: 17018259
-
CK2 signaling in androgen-dependent and -independent prostate cancer.J Cell Biochem. 2006 Oct 1;99(2):382-91. doi: 10.1002/jcb.20847. J Cell Biochem. 2006. PMID: 16598768 Review.
-
New protein kinase CK2 inhibitors: jumping out of the catalytic box.Chem Biol. 2009 Feb 27;16(2):112-20. doi: 10.1016/j.chembiol.2009.01.004. Chem Biol. 2009. PMID: 19246001 Review.
Cited by
-
[Protein kinase CK2 and human malignant tumors].Zhongguo Fei Ai Za Zhi. 2012 Jul;15(7):439-45. doi: 10.3779/j.issn.1009-3419.2012.07.09. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22814265 Free PMC article. Review. Chinese. No abstract available.
-
Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.Mol Cancer Ther. 2016 Aug;15(8):1931-42. doi: 10.1158/1535-7163.MCT-15-0987. Epub 2016 May 18. Mol Cancer Ther. 2016. PMID: 27196773 Free PMC article.
-
Emodin Bidirectionally Modulates Macrophage Polarization and Epigenetically Regulates Macrophage Memory.J Biol Chem. 2016 May 27;291(22):11491-503. doi: 10.1074/jbc.M115.702092. Epub 2016 Mar 23. J Biol Chem. 2016. PMID: 27008857 Free PMC article.
-
Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.Genome Biol. 2017 Aug 11;18(1):153. doi: 10.1186/s13059-017-1282-3. Genome Biol. 2017. PMID: 28800781 Free PMC article.
-
Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.Mol Cell Biochem. 2015 Aug;406(1-2):151-61. doi: 10.1007/s11010-015-2433-z. Epub 2015 May 12. Mol Cell Biochem. 2015. PMID: 25963666
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
